MedTrace Logo

Perioperative Glutamine Supplementation and Cachexia

NCT05023499 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2021-08-26

No results posted yet for this study

Summary

Background Sarcopenia is characterized by the degenerative loss of skeletal muscle and is associated with increased adverse surgical outcomes. Glutamine is considered as an immune-modulating formula, which may stimulate protein synthesis in the skeletal muscle but also inhibited protein-degradation. In this study, the investigators calculate the area and volume psoas major muscle (PMMA; PMMV) of the third lumbar vertebral body as the reference of skeletal muscle. The aim of this study is to investigate whether perioperative glutamine supplementation restores atrophy of psoas muscle.

Conditions

  • Glutamine; Metabolic Disorder
  • Cachexia

Interventions

DRUG

SYMPT-X Glutamine, Oral Powder for Reconstitution

erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2019-06-30
Completion
2021-08-14

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05023499 on ClinicalTrials.gov